Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- JPMA Committee to Promote Patient-friendly Healthcare
May 20, 2002
- Kobe Foundation, Kirin to Commercialize Cord Blood Stem Cells
May 20, 2002
- Importance of Drug Patents Emphasized: Union Symposium
May 20, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
May 20, 2002
- Teijin to Form Teijin Pharma by Spinning Off Drug Division in 2003
May 20, 2002
- Terumo to Transfer Dialyzer Business to Asahi Medical
May 20, 2002
- BUSINESS NEWS IN BRIEF
May 20, 2002
- Freund: US Subsidiary Boosts Sales, Profits
May 20, 2002
- NEW PRODUCTS
May 20, 2002
- Koike Sanso to Market Infectious Medical Waste Disposal System
May 20, 2002
- Research Starts on Humanized Antibodies for Treatment of Hepatitis C: Korosho
May 20, 2002
- MEDICAL DEVICE NEWS IN BRIEF
May 20, 2002
- REGULATORY NEWS IN BRIEF
May 20, 2002
- Sanko Junyaku to Create New Company to Commercialize PALSAR Method
May 20, 2002
- Pharmacies Entertain Hope of Generic Substitution
May 20, 2002
- Sanko Junyaku, Tokai Univ. to Codevelop Reagents Using PALSAR
May 20, 2002
- President-elect Kobori to Follow Handa's Policy: MPC
May 13, 2002
- DIAGNOSTIC NEWS IN BRIEF
May 13, 2002
- SSP, Kirin Screen New LMW Compounds for Drug Discovery
May 13, 2002
- MEDICAL DEVICE NEWS IN BRIEF
May 13, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…